ReviewJournal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia2017
Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
Review in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Trial
- Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.Journal of neuro-oncology · 2020Trial
- KDM6B promotes VEGFA expression and vasculogenic mimicry in glioblastoma cells under hypoxia conditions.Experimental brain research · 2026Article
- Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.Nature medicine · 2024Article
- An In Vitro Model of Glioma Development.Genes · 2023Article
- Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy.Cancers · 2022Review
- Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.International journal of clinical oncology · 2021Article
- Clinical applications of artificial intelligence and radiomics in neuro-oncology imaging.Insights into imaging · 2021Review
- Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.PloS one · 2021Article
- Article
- Early imaging marker of progressing glioblastoma: a window of opportunity.Journal of neuro-oncology · 2020Article
- The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.Clinical and translational radiation oncology · 2020Article
- Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma.Frontiers in oncology · 2020Article
- Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation.Radiation oncology journal · 2019Article
- Review
- Review
- Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment.Medical sciences (Basel, Switzerland) · 2018Article
- Survival of patients with prior anti-angiogenic therapy.Neuro-oncology · 2018Article
- Molecular Determinants of Malignant Brain Cancers: From Intracellular Alterations to Invasion Mediated by Extracellular Vesicles.International journal of molecular sciences · 2017Review
- Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Bevacizumab (BEV) is a common treatment for recurrent glioblastoma (GBM). After progression on BEV, there is no consensus on subsequent therapy, as multiple chemotherapy trials have failed to demonstrate discernible activity for salvage. A previous review (995 patients) estimated a progression free survival (PFS) on BEV of 4.2months (SD±2.1) with an overall survival (OS) after progression on BEV at 3.8months (SD±1). We endeavored to establish a more rigorous historical control, both as a benchmark for efficacy, and a prognostic tool for clinical practice. A comprehensive literature review was performed utilizing PubMed and societal presentation abstracts. A total 2388 patients from 53 arms of 42 studies were analyzed in three groups: 1) thirty-two studies in which survival post-BEV was determined by subtracting PFS from OS (2045 patients): PFS on BEV=4.38months (95% CI 4.09-4.68); OS post-BEV=3.36months (95% CI 3.12-3.66); 2) two studies (94 patients) in which OS post-BEV is reported: OS=3.26 (95% CI 2.39-4.42); 3) eight studies of salvage therapy after progression on BEV (249 patients): of OS post-BEV=4.46months (95% CI 3.68-5.54). These estimates provide a firm historical control for PFS on BEV, as well as OS after disease progression on BEV therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.